Management of epilepsy in pregnancy: therapeutic aspects.

Br J Hosp Med

Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham.

Published: October 1996

Epilepsy is one of the most common chronic illnesses encountered by obstetricians, affecting around 1 in 200 women attending antenatal clinics. Epilepsy and antiepileptic drugs may have significant effects on pregnancy and pregnancy may affect the epilepsy. It is therefore vital that those looking after these women have a knowledge of the potential problems.

Download full-text PDF

Source

Publication Analysis

Top Keywords

management epilepsy
4
epilepsy pregnancy
4
pregnancy therapeutic
4
therapeutic aspects
4
aspects epilepsy
4
epilepsy common
4
common chronic
4
chronic illnesses
4
illnesses encountered
4
encountered obstetricians
4

Similar Publications

Introduction: According to the World Health Organization, 44 million people worldwide suffer from Alzheimer's disease. Abnormal movements are atypical symptoms of Alzheimer's disease.

Case Description: An 87-year-old woman, followed for Alzheimer's disease, experienced abnormal movements.

View Article and Find Full Text PDF

Clinical manifestations and molecular genetics of seven patients with Niemann-Pick type-C: a case series with a novel variant.

J Pediatr Endocrinol Metab

January 2025

Department of Pediatric Metabolism and Ankara University Rare Diseases Application and Research Center, Ankara University Faculty of Medicine, Ankara, Türkiye.

Objectives: Niemann-Pick type C (NPC) is a rare, autosomal recessive, neurodegenerative disorder caused by biallelic pathogenic variants in the or genes, leading to lysosomal lipid accumulation. NPC has an incidence of 1 in 100,000 live births and presents with a wide range of symptoms affecting visceral organs and the central nervous system. We aim to describe the diverse clinical presentations of NPC through case studies.

View Article and Find Full Text PDF

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Analysis of initial seizure characteristics in patients with infantile onset genetic epilepsy.

Brain Dev

January 2025

Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul National University College of Medicine, 101 Daehakro, Jongno-Gu, Seoul 03080, Republic of Korea. Electronic address:

Objective: The present study aimed to investigate the initial clinical features of infantile-onset genetic epilepsy and compare initial seizure variables and responses to sodium channel blockers between SCN1A and non-SCN1A group.

Methods: We selected 122 patients, comprising 58 patients with SCN1A mutations and 64 patients with mutations in other than SCN1A, from our institutional database.

Results: Patients identified in the SCN1A group tended to present with fever, prolonged seizure duration, and hemiclonic seizure semiology.

View Article and Find Full Text PDF

Seizures are a frequent complication in glioma. Incidence of brain tumor-related epilepsy (BTRE) in high-grade glioma (HGG) is an estimated > 25% and in low-grade glioma (LGG) is approximately 72%. Two first-line antiseizure medications (ASMs) for BTRE include levetiracetam (LEV) and valproic acid (VPA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!